Advertisement

Topics

Search Results for "Cvs Minute Clinic Shingles Vaccine"

22:10 EDT 25th April 2017 | BioPortfolio

Matching Channels

Varicella

Varicella zoster virus (VZV) is one of eight herpes viruses known to infect humans (and other vertebrates). Varicella-zoster virus is known by many names, including: chickenpox virus, varicella viru...

HPV vaccine

Rotavirus Vaccine GSK

Smallpox Vaccine MVA

Poliovirus Vaccine OPV

Matching News

GSK seeks EU approval for shingles vaccine

GlaxoSmithKline (GSK) has submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval for its shingles vaccine candidate dubbed Shingrix, for herpes z...

UPDATE: GSK is staging a comeback with a new Shingles Vaccine

GSK is banishing concerns about its health with a BLA submission for Shingrix, which has outperformed Merck’s standard and could bring GSK close to €1Bn. London-based GSK has just submitted a ...

BRIEF-GlaxoSmithKline submits marketing application for shingles vaccine to EMA

* GSK announces EU regulatory submission of candidate vaccine for prevention of shingles

GSK Announces EU Regulatory Submission of Candidate Vaccine for Prevention of Shingles

GlaxoSmithKline plc (LSE/NYSE: GSK) has announced the regulatory submission of a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) seeking approval for its candidate shi...

GSK files shingles vaccine in EU

GlaxoSmithKline has filed its shingles vaccine in Europe, as it seeks to boost sales with a new wave of drugs. The EU filing of Shingrix follows a US filing last month for the drug, which analysts be...

GSK Seeking EU Approval for Shingrix Shingles Vaccine

NewsGSK announces EU regulatory submission of candidate vaccine for prevention of shingles—follows regulatory submissions in U.S. and Canada.

GSK seeks EMA approval for shingles vaccine

A marketing authorization application has been submitted to the European Medicines Agency by GlaxoSmithKline for its shingles -More- 

GSK and Daiichi Sankyo JV submits NDA for candidate shingles vaccine in Japan

GlaxoSmithKline (GSK) and Daiichi Sankyo joint venture (JV) Japan Vaccine Co has submitted a New Drug Application (NDA) in Japan for candidate shingles vaccine, Shingrix.

Matching PubMed Articles

A critical appraisal of 'Shingrix', a novel Herpes Zoster Subunit (HZ/Su or GSK1437173A) vaccine for Varicella Zoster Virus.

HZ/Su, branded as 'Shingrix', is one of the newest vaccines to be submitted for multi-national regulatory approval. It is targeted to prevent shingles, predominantly affecting the elderly, but a globa...

Vaccination Coverage Among Adults With Diagnosed Diabetes: United States, 2015.

Data from the National Health Interview Survey •Among adults aged 18 and over with diagnosed diabetes, 61.6% had an influenza vaccine in the past year. •A total of 52.6% of adults with diagnosed d...

Safety profile of the varicella vaccine (Oka vaccine strain) based on reported cases from 2005 to 2015 in Japan.

As of 2014, routine vaccination strategies in Japan have included the varicella vaccine. Given the widespread use of the vaccine, it is important to investigate the safety profile of the vaccine strai...

Modeling HIV vaccine trials of the future.

Models of implementation of known-effective interventions for HIV prevention indicate that an efficacious vaccine to prevent HIV infection would be critical for controlling the HIV pandemic. Key issue...

Adult immunisation: General points, hot topics and perspectives.

Vaccination in immunocompetent adult mainly concerns booster vaccination against diphtheria, tetanus, polio and pertussis. Some chronic diseases may also require the achievement of pneumococcal and in...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement